Hsin-Hui Huang
YOU?
Author Swipe
View article: Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Experimental data userd in the article including Olink, CyTOF populational frequencies, Serology and TCRseq beta chain.
View article: Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over ti…
View article: Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
CyTOF antibody panel details.
View article: Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.
View article: Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using sta…
View article: Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
OS Multivariate analysis showing that markers significant during univariate analysis are not significant during multivariate analysis.
View article: Applying AI Mind Mapping to Empower Patients with Schizophrenia
Applying AI Mind Mapping to Empower Patients with Schizophrenia Open
Schizophrenia affects patients’ organizational thinking ability to identify problems. The main objective of this purposive sampling survey study is to explore healthcare consultants’ application of AI mind maps to educate patients with sch…
View article: Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Experimental data userd in the article including Olink, CyTOF populational frequencies, Serology and TCRseq beta chain.
View article: Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.
View article: Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using sta…
View article: Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.
View article: Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over ti…
View article: Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using sta…
View article: Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Experimental data userd in the article including Olink, CyTOF populational frequencies, Serology and TCRseq beta chain.
View article: Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over ti…
View article: Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
CyTOF antibody panel details.
View article: Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
OS Multivariate analysis showing that markers significant during univariate analysis are not significant during multivariate analysis.
View article: Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
OS Multivariate analysis showing that markers significant during univariate analysis are not significant during multivariate analysis.
View article: Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
CyTOF antibody panel details.
View article: Figure 4 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure 4 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Cancer antigen detection and T-cell clonal dynamics associated with treatment and response. A, Heatmap showing cancer antigen detection by ELISA for all samples. The color represents the log10 scale antibody titers. Posit…
View article: Figure 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Cellular dynamics in HL during checkpoint blockade treatment. A, Cell type composition of major cell groups (myeloid and lymphoid) for all available samples at baseline. This bar plot shows the composition and variation of cellular …
View article: Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over ti…
View article: Figure 4 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure 4 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Cancer antigen detection and T-cell clonal dynamics associated with treatment and response. A, Heatmap showing cancer antigen detection by ELISA for all samples. The color represents the log10 scale antibody titers. Posit…
View article: Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using sta…
View article: Figure 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Association of plasma cytokines with clinical benefit. A, C, and E, PFS survival analysis shows the Kaplan–Meier curves for VEGFR2, CXCL9, and MUC16, respectively. Statistics using log-rank test and Cox proportional ha…
View article: Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.
View article: Data from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Data from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
To investigate the cellular and molecular mechanisms associated with targeting CD30-expressing Hodgkin lymphoma (HL) and immune checkpoint modulation induced by combination therapies of CTLA4 and PD1, we leveraged Phase 1/2 multicenter ope…
View article: Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over ti…
View article: Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Experimental data userd in the article including Olink, CyTOF populational frequencies, Serology and TCRseq beta chain.
View article: Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
OS Multivariate analysis showing that markers significant during univariate analysis are not significant during multivariate analysis.